Akari Therapeutics
Executives
View the org chart displaying its 9 main executives
Most searched biographies at Akari Therapeutics
- Samir Patel, Interim Chief Executive Officer & Director
- Ray Prudo, Executive Chairman of the Board
- Michael Grissinger, Director
Popular executive movements at Akari Therapeutics
- Samir Patel, who was Director, is promoted to Interim Chief Executive Officer & Director (posted on May 2 2024).
- Rachelle Jacques, President and Chief Executive Officer, has left the company (posted on May 2 2024).
- Melissa Bradford-Klug, Chief Operating Officer, has left the company (posted on May 2 2024).
Click here to view some more movements at Akari Therapeutics
Create your alert
to follow the executive moves at Akari Therapeutics.
Biotechnology
Akari Therapeutics has 2,286 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Karius has just announced a $100 Million fundraising (posted on May 3 2024).
- Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (posted on May 2 2024).
Popular contacts in Biotechnology
News
Press releases by Akari Therapeutics
- Akari Therapeutics Narrows Pipeline Focus | Akari Therapeutics
- Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy | Akari Therapeutics
- Press Releases | Akari Therapeutics
- Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress | Akari Therapeutics
- Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) | Akari Therapeuti
- Press Releases | Akari Therapeutics
- Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth Strategies | Akari Therapeutics
- Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting | Akari Therapeutics
- Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress | Akari Therapeutics
- Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting | Akari Therapeutics
- View more press releases Close
Social media about Akari Therapeutics
- Akari Therapeutics on Wikipedia, Google News & Yahoo Finance
- Akari Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Ray Prudo 
Call Akari Therapeutics at +1 646...
